SummaryUnresponsiveness to therapy is a hallmark feature of advanced metastatic melanoma. However, the discovery of BRAF-activating mutations in approximately 50% of human melanomas has provided an attractive therapeutic target. Here, we discuss two recent publications focusing on the mutant BRAF kinase inhibitor PLX4032 that validate oncogene-targeted melanoma therapy
In recent years, melanoma has become a poster-child for the development of oncogene-directed targete...
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF V600-mutant m...
The protein kinase BRAF is mutated ∼40% of human melanomas. BRAF is a component of the RAS/RAF/MEK/E...
SummaryUnresponsiveness to therapy is a hallmark feature of advanced metastatic melanoma. However, t...
Historically, patients with advanced cutaneous melanoma have a poor prognosis and limited treatment ...
Melanomas are the most insidious type of skin cancers, with more than 76,000 new cases and over 9100...
Introduction: The clinical activity of BRAF inhibitor (BRAF-I) therapy is a major breakthrough in th...
PURPOSE: About 65% to 70% of melanomas harbor a mutation in v-raf murine sarcoma viral oncogene homo...
PURPOSE: About 65% to 70% of melanomas harbor a mutation in v-raf murine sarcoma viral oncogene homo...
Melanomas exhibit the highest rate of somatic mutations among all different types of cancers (with t...
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mut...
The prognosis of patients with metastatic melanoma is poor and not influenced by systemic therapy wi...
Malignant melanoma is associated with poor clinical prognosis; however, novel molecular and immune t...
Introduction: After its identification as an oncogene in 2002, mutant BRAF has become the target of ...
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mut...
In recent years, melanoma has become a poster-child for the development of oncogene-directed targete...
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF V600-mutant m...
The protein kinase BRAF is mutated ∼40% of human melanomas. BRAF is a component of the RAS/RAF/MEK/E...
SummaryUnresponsiveness to therapy is a hallmark feature of advanced metastatic melanoma. However, t...
Historically, patients with advanced cutaneous melanoma have a poor prognosis and limited treatment ...
Melanomas are the most insidious type of skin cancers, with more than 76,000 new cases and over 9100...
Introduction: The clinical activity of BRAF inhibitor (BRAF-I) therapy is a major breakthrough in th...
PURPOSE: About 65% to 70% of melanomas harbor a mutation in v-raf murine sarcoma viral oncogene homo...
PURPOSE: About 65% to 70% of melanomas harbor a mutation in v-raf murine sarcoma viral oncogene homo...
Melanomas exhibit the highest rate of somatic mutations among all different types of cancers (with t...
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mut...
The prognosis of patients with metastatic melanoma is poor and not influenced by systemic therapy wi...
Malignant melanoma is associated with poor clinical prognosis; however, novel molecular and immune t...
Introduction: After its identification as an oncogene in 2002, mutant BRAF has become the target of ...
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mut...
In recent years, melanoma has become a poster-child for the development of oncogene-directed targete...
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF V600-mutant m...
The protein kinase BRAF is mutated ∼40% of human melanomas. BRAF is a component of the RAS/RAF/MEK/E...
DOI
Add to ORKG